Ponatinib

Generic Name
Ponatinib
Brand Names
Iclusig
Drug Type
Small Molecule
Chemical Formula
C29H27F3N6O
CAS Number
943319-70-8
Unique Ingredient Identifier
4340891KFS
Background

Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.

Indication

1.用于治疗达沙替尼或尼洛替尼治疗无效的慢性期、进展期或急性期的慢性粒细胞白血病(CML);或不能耐受达沙替尼或尼洛替尼者,以及临床不适合用伊马替尼进行后续治疗的患者;或T315I突变者。

2.用于治疗达沙替尼治疗无效的费城染色体阳性急性淋巴细胞白血病(Ph+ALL);或不能耐受达沙替尼者,以及临床不适合用伊马替尼进行后续治疗的患者;或T315I突变者。

Associated Conditions
Accelerated Phase Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukaemias (ALL), Chronic Phase Chronic Myeloid Leukemia, Blast phase Chronic myeloid leukemia
Associated Therapies
-

Retrospective Evaluation of CML Patients in the National Compassionate Program

First Posted Date
2015-05-19
Last Posted Date
2022-10-26
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Target Recruit Count
38
Registration Number
NCT02448095
Locations
🇮🇹

ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE, Lecce, Italy

🇮🇹

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico UOC Oncoematologia- Padiglione Marcora 2° piano, Milano, Italy

🇮🇹

Azienda Ospedaliera "S.Gerardo", Monza, Italy

and more 7 locations

Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib

First Posted Date
2015-03-26
Last Posted Date
2022-01-05
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Target Recruit Count
16
Registration Number
NCT02398825
Locations
🇮🇹

Azienda Ospedaliera Di Bologna Policlinico S. Orsola - Malpighi, Bologna, Italy

🇮🇹

Azienda Ospedaliero - Universitaria Ospedali Riuniti Umberto I - G.M. Lancisi - G. Salesi, Ancona, Italy

🇮🇹

Università di Catania - Cattedra di Ematologia - Ospedale "Ferrarotto", Catania, Italy

and more 34 locations

Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma

Not Applicable
Withdrawn
Conditions
Interventions
First Posted Date
2013-06-27
Last Posted Date
2015-12-18
Lead Sponsor
Washington University School of Medicine
Registration Number
NCT01888562

A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor

Phase 2
Completed
Conditions
Interventions
First Posted Date
2013-06-11
Last Posted Date
2018-05-18
Lead Sponsor
Ariad Pharmaceuticals
Target Recruit Count
45
Registration Number
NCT01874665
Locations
🇺🇸

Oregon Health & Sciences University, Site #048, Portland, Oregon, United States

🇺🇸

Fox Chase Cancer Center, Site #012, Philadelphia, Pennsylvania, United States

🇺🇸

Massachusetts General Hospital, Site #047, Boston, Massachusetts, United States

and more 1 locations

Ponatinib for Advanced Medullary Thyroid Cancer

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2013-04-24
Last Posted Date
2017-02-15
Lead Sponsor
National Institutes of Health Clinical Center (CC)
Target Recruit Count
3
Registration Number
NCT01838642
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Ponatinib in Advanced NSCLC w/ RET Translocations

Phase 2
Completed
Conditions
Interventions
First Posted Date
2013-03-19
Last Posted Date
2019-12-24
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
9
Registration Number
NCT01813734
Locations
🇺🇸

University of Maryland, Baltimore, Maryland, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

Karmanos Cancer Institute, Detroit, Michigan, United States

and more 2 locations

Ponatinib for Squamous Cell Lung and Head and Neck Cancers

First Posted Date
2013-01-07
Last Posted Date
2014-12-23
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
3
Registration Number
NCT01761747
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

and more 1 locations

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

First Posted Date
2012-07-26
Last Posted Date
2014-11-17
Lead Sponsor
Ariad Pharmaceuticals
Target Recruit Count
307
Registration Number
NCT01650805
Locations
🇺🇸

US Oncology - Providence Health System, Site #167, Burbank, California, United States

🇺🇸

UCLA Department of Medicine, Site #027, Los Angeles, California, United States

🇺🇸

Seattle Cancer Care Alliance, Site #100, Seattle, Washington, United States

and more 167 locations

Phase II Front-line Ponatinib in Adult Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia.

First Posted Date
2012-07-16
Last Posted Date
2021-11-30
Lead Sponsor
Incyte Corporation
Target Recruit Count
44
Registration Number
NCT01641107
Locations
🇮🇹

Dipartimento Area Medica - Presidio Ospedaliero "C. e G.Mazzoni", Ascoli, Italy

🇮🇹

Azienda Ospedaliero - Universitaria Ospedali Riuniti Umberto I - G.M. LANCISI - G. SALESI, Ancona, Italy

🇮🇹

Azienda Ospedaliera - Papa Giovanni XXIII, Bergamo, Italy

and more 39 locations
© Copyright 2024. All Rights Reserved by MedPath